Sentences with phrase «over growth shares»

Positions that have recently come undone include betting on steepening yield curves and inflation expectations (inflation - linked over nominal bonds)-- and in equity markets, picking value over growth shares.

Positions that have recently come undone include betting on steepening yield curves and inflation expectations (inflation - linked over nominal bonds)-- and in equity markets, picking value over growth shares.

Not exact matches

I am pleased to announce that our Board of Directors declared a 7 % increase in our quarterly cash dividend to $ 0.77 per share, marking 14 consecutive years of dividend increases with a compound annual growth rate of about 10 % over that period.

But Sexsmith says Signature's earnings - per - share growth — 11 % annually over the past five years on a compounded basis, even accounting for the taxi - permit stumble — shows management's strength.

The volatility in Bombardier's shares could partly be due to the culture of seeking growth through product innovation, so there will be periods when new offerings are hitting their stride and periods when there is uncertainty over the outcome.

Moreover, the rate of growth in the fraction of non-employers (28.2 percent) run by women has been higher than the rate of increase in their share of non-employers (23 percent) over the past five years.

Under Armour warned investors that sales growth would slow over the next two years, and the news sent shares down sharply on Tuesday.

Still, he expects good share - price growth over the next few years, and if Europe's economic fortunes improve, then investors could see stocks soar.

Canopy Growth Corp. is currently valued at just over $ 7.5 billion yet loses about 12 cents a share.

The market share within craft has grown from 1 % to over 3 % over that period within the U.S. Heineken's beer volume growth, like other big brewers, is far slower, rising 3.6 % in the Americas in the first half of 2015.

When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect over the next decade or so comprise four building blocks: the starting dividend yield, projected growth in real earnings per share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the price / earnings (P / E) multiple.

«Even if smartphone replacement cycles continue to lengthen, we see Apple delivering 4 % revenue and 16 % (earnings per share) growth over the next three years with services the primary growth engine,» Morgan Stanley's Huberty wrote.

And Shake Shack's (shak) shares have fallen back to earth, plummeting below $ 35 from over $ 90, as investors realized that the small burger chain's growth couldn't justify its Mars - orbit valuations.

Without increasing the tax share of output, 1 per cent real growth over the next 40 years will yield an inflation - adjusted increase in tax revenue per capita of about 50 per cent.

Emerging markets also account for over 50 % of world GDP, and have been responsible for the lion's share of global growth ever since the 2008 financial crisis, but capital has flooded out of them as the Federal Reserve has tightened its monetary policy and the limits of China's economic model have become apparent.

If Netflix sees high revenue increases over the next couple of years, based on strong subscriber growth, customer retention, and low marketing spend, he predicts the share price could reach $ 480.

Skeptics see a company whose earnings - per - share growth, which has averaged 30 % annually over the past five years, is bound to slow down, which makes it tough to justify paying 23 times estimated 2017 earnings for the stock.

Twitter shares have been under severe pressure of late, down more than 40 percent in the last six months as uncertainty over the company's leadership structure and growth potential weighed on investors.

Though productivity apps only make up a small 4 % of time spent, their share doubled over the past year, higher growth than any other category.

J.P. Morgan initiates coverage for Spotify shares with an overweight rating, predicting strong user growth over the next five years.

The stock is trading at the high end of its historical range, but its «industry leading earnings and free cash flow growth» make up for that higher multiple, he said The stock is currently trading at $ 191 a share, but Hansen said it will hit $ 220 over the next 12 - months.

Canada's most profitable business over the past five years, tallying $ 41.24 billion, also enjoys the best five - year share growth among Canada's Big Five Banks at 74 %.

The stock has climbed by 50 % over the last 12 months — partly due to the 41 % year - over-year earnings per share growth it saw in Q3 2013 — but Campbell thinks it still has room to run.

Asian shares ended mixed on Tuesday amid optimism over the global growth outlook.

J.P. Morgan initiates coverage of Spotify shares with an overweight rating, predicting strong user growth over the next five years.

J.P. Morgan raises its rating to overweight from neutral for New York Times Company's shares, predicting strong profit growth over the next two years.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

While Penney at least reported growth over the holidays, the results suggest lost market share, given that the overall industry outpaced it with 4 % growth, as did rivals such as Kohl's (kss) and Target (tgt).

But anyone hoping for the kind of stock growth Shoppers enjoyed over the past decade — when its share price climbed from less than $ 18 to, at one point, over $ 55 — will be disappointed.

This growth rate is the compound annual growth rate of cash dividends per common share of stock over the last 5 years.

The company has demonstrated a pattern of positive earnings per share growth over the past two years.

Indeed, the strong growth of investor housing loans has driven the growth in household debt (as a share of disposable incomes) over recent years and contributed to a rise in both housing prices and dwelling construction.

Earnings per Share Growth Measures the growth in reported earnings per share over the specified past time peShare Growth Measures the growth in reported earnings per share over the specified past time pGrowth Measures the growth in reported earnings per share over the specified past time pgrowth in reported earnings per share over the specified past time peshare over the specified past time period.

Over time this means that households will retain a growing share of China's total production of goods and services (at the expense of the elite, of course, who benefitted from subsidized borrowing costs) and so not only will they not be hurt by a sharp fall in GDP growth, but their consumption will increasingly drive growth and innovation in China.

If you multiply China's GDP growth by its share of global GDP, you will find that Chinese growth over the last few years has comprised a larger share of global GDP growth than that of any other country.

Any feedback into prices is dampened by the low level of wage growth, rebalancing of factor shares, and a relatively low correlation that has developed over time re the price - wage relationship.

If a breakup of the company delivers the cost savings that Peltz believes and improves pre-tax margins to 17 % and spurs 8 % revenue growth for 15 years, the stock is worth over $ 90 / share.

Shares of ARRIS International plc (NASDAQ: ARRS), a media entertainment and data communications solutions provider, lost more than 12 percent of its value over the past year and doesn't reflect the company's «robust growth opportunities» ahead, according to one Wall Street analyst...

Bad weather probably played a part, which helps explain why online sales were up over 2 % as shoppers bought at the keyboard, but tepid income growth shares a large part of the blame.

Asian shares dipped Wednesday, mirroring a sell - off on Wall Street on worries over slowing growth and falling profits.

These three categories are responsible for 83 percent of nominal spending growth over the next decade and 150 percent of spending growth as a share of GDP (with other budget categories shrinking).

«From a capital allocation perspective, we will always prioritize re-investments in our growth priorities over share buybacks,» said David Crundwell, senior vice president, corporate affairs, at Thomson Reuters.

In a more optimistic scenario of 5 % compound annual NOPAT growth over the next decade, the stock is worth $ 100 / share today — a 54 % upside.

Upside reward potential is strong as the stock has to go over $ 82 / share to trade at a value that implies the company's profits will experience a 0 % decline, a no - growth scenario.

Over the past 30 years, during which earnings growth hasn't been stellar, market values have instead been driven by Federal Reserve - induced low interest rates leading to corporate share repurchase strategies and merger and acquisition activity.

These businesses have leading market share positions in almost every retail product, and experienced solid volume growth over the past year.

The company has demonstrated a pattern of positive earnings per share growth over the past year.

With just over half of the S&P 500 companies having reported, the largest U.S. companies are on course to post earnings per share growth of 23.2 % from a year ago, according to FactSet But apparently, the best growth in -LSB-...]

The company shared on Thursday that it's targeting U.S. same restaurant sales growth of 2 % to 4 % over the next five years.

Radius Health (RDUS)- Beneficial owner Biotech Growth NV continues to add to its stake, this time scooping up 40,000 shares and bringing its total stake to over 6 million shares.